title: Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies.
abstract: The outcome of 34 women with anti-Yo-associated paraneoplastic cerebellar degeneration was reviewed. Three patients had not developed cancer after more than 4 years of follow-up. The only independent predictor for survival was the type of associated tumor (risk ratio, 1.79; 95% CI, 1.02 to 3.12). Median survival was 100 months for patients with breast cancer and 22 for those with gynecologic cancer. Although paraneoplastic cerebellar degeneration leads to the diagnosis of cancer in 63% of the patients, cancer progression was the cause of death in 52%.
authors.affiliation: Services of Neurology, Ciutat Sanitaria Universitaria de Bellvitge, Hospitalet, Spain.
authors.forename: I
authors.initials: I
authors.lastname: Rojas
authors.forename: F
authors.initials: F
authors.lastname: Graus
authors.forename: F
authors.initials: F
authors.lastname: Keime-Guibert
authors.forename: R
authors.initials: R
authors.lastname: Reñé
authors.forename: J Y
authors.initials: JY
authors.lastname: Delattre
authors.forename: J M
authors.initials: JM
authors.lastname: Ramón
authors.forename: J
authors.initials: J
authors.lastname: Dalmau
authors.forename: J B
authors.initials: JB
authors.lastname: Posner
mesh_terms: D000328:Adult; D001943:Breast Neoplasms / Q000503:physiopathology; D005260:Female; D005833:Genital Neoplasms, Female / Q000503:physiopathology; D006801:Humans; D008875:Middle Aged; D020362:Paraneoplastic Cerebellar Degeneration / Q000401:mortality / Q000503:physiopathology*; D011379:Prognosis; D016019:Survival Analysis; D013997:Time Factors